Shield Therapeutics (LON:STX) Stock Crosses Below Fifty Day Moving Average of $7.02

Shield Therapeutics plc (LON:STX – Get Rating)’s stock price crossed below its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of GBX 7.02 ($0.09) and traded as low as GBX 6.10 ($0.07). Shield Therapeutics shares last traded at GBX 6.40 ($0.08), with a volume of 1,647,125 shares.

Analysts Set New Price Targets

Separately, Peel Hunt reissued a “buy” rating on shares of Shield Therapeutics in a report on Thursday, February 9th.

Shield Therapeutics Price Performance

The company has a current ratio of 2.60, a quick ratio of 2.16 and a debt-to-equity ratio of 0.38. The firm has a market capitalization of £37.48 million, a PE ratio of -71.11 and a beta of 0.83. The company has a fifty day moving average price of GBX 7.02 and a two-hundred day moving average price of GBX 8.31.

Insider Activity

In other Shield Therapeutics news, insider Greg Madison sold 466,395 shares of the company’s stock in a transaction that occurred on Friday, December 23rd. The stock was sold at an average price of GBX 7 ($0.09), for a total transaction of £32,647.65 ($39,789.95). Company insiders own 42.23% of the company’s stock.

About Shield Therapeutics

(Get Rating)

Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of clinical stage pharmaceuticals to treat unmet medical needs. The company's lead product is Accrufer/Feraccru, a non-salt based oral therapy for the treatment of iron deficiency with or without anemia in adults.